RxDoctor Payments DataLook up a doctor →

Fintepla: payments to doctors

Payments that named Fintepla as the associated drug or biological, reported under the Sunshine Act for program years 20192025.

Total reported
$4.5M
Providers
6,171
Transactions
33,562
Average per transaction
$134

The per-transaction average — $134 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 6,171 providers the average total is $731, but that average hides a very steep distribution.

Companies reporting these payments

CompanyTotal reportedShare
UCB, Inc.$3,915,61786.8%
Zogenix Inc.$323,4447.2%
UCB SA$152,7913.4%
UCB Biosciences Inc.$114,4302.5%
Nippon Shinyaku Co.,ltd$4,6460.1%
← All drugs & devices